Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation, Ipilimumab, and Nivolumab in Metastatic NSCLC
NCT03168464Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2017
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Weill Cornell Medicine. Started Oct 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03168464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168464.